# Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.

> **NCT05628116** · PHASE1 · COMPLETED · sponsor: **PHARMENTERPRISES LLC** · enrollment: 38 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** XC243 50 mg single
- **DRUG:** XC243 100 mg single
- **DRUG:** Placebo single
- **DRUG:** XC243 200 mg single-dose food effect
- **DRUG:** Placebo single-dose food effect
- **DRUG:** XC243 200 mg multiple
- **DRUG:** Placebo multiple

## Key facts

- **NCT ID:** NCT05628116
- **Lead sponsor:** PHARMENTERPRISES LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-28
- **Primary completion:** 2023-09-21
- **Final completion:** 2023-09-21
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05628116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05628116, "Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05628116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*